Recombinant adeno-associated virus transfecting dendritic cells based gene immunotherapy (AAV-DC gene immunotherapy)

Adoptive T cell treatment of cytotoxic T lymphocytes generated from autologous dendritic cells transfected with recombinant human adeno-associated virus containing tumor antigen gene

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-09000586

Enrollment

Unknown

Registered

2009-11-06

Start date

2008-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CANCER

Interventions

AAV-DC:Adoptive T cell treatment of cytotoxic T lymphocytes generated from autologous dendritic cells transfected with recombinant human adeno-associated virus containing tumor antigen gene

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with malignant solid tumor proved by histopathology or cytology; 2. With positive tumor antigens by immunohistochemical stain or positive serum tumor markers; 3. With an interval of at least 4 weeks from last operation, radiotherapy, chemotherapy and other treatments which could have influence on immunity; 4. Age between 18 and 70 years old;5. ECOG Performance Status =60; 6. Expectant survival >=3 months; 7. Count of blood cell before treatment should in following range: Neuo>=1.5*10^9/L, Hb>=90g/L, and PLT >=60*10^9/L; 8. Liver function is normal or the raise of ALT and AST 50ml/min; 10. Asymptomatic brain metastasis; 11. No history of severe hypersensitive constitution and allergy to cytokines GM-CSF and IL-2; 12. Inform of consents were signed voluntarily.

Exclusion criteria

Exclusion criteria: 1. Negative of tumor antigen by immunohistochemical stain and serum tumor markers; 2. Intolerance to insert catheter of central vein to separate peripheral blood mononuclear cells; 3. Patients having operation, radiotherapy, chemotherapy and other treatments which may have influence on immunity within 4 weeks; 4. Symptomatic brain metastasis; 5. Uncontrolled diseases such as congestive heart failure, myocardial infarction within last 3 months, coronary heart disease, and arrhythmia; 6. Hypersensitive constitution or allergy to drugs in treatment; 7. History of other tumors except for those of cervical carcinoma in situ or skin basal cell carcinoma who had been completely treated and without relapse in last 5 years; 8. Pregnant or lactated women; 9. Non-ability people; 10. Patients who investigators consider should not be enrolled.

Design outcomes

Primary

Measure	Time frame
safety;	—

Countries

China

Contacts

Public ContactDr. Jun Ren

renjun@bjcancer.org+86 010 88196356/13911568563

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026